Jubilant Ingrevia Limited (JUBLINGREA)

Chemicals · Chemicals & Petrochemicals · NSE · Updated 15 July 2026

₹724.05 ↓ 12.06% (1Y)

🎯 Key Takeaways

Jubilant Ingrevia Limited is in a strategic transition phase, shifting from commodity chemicals toward higher-margin Specialty Chemicals and Nutrition Health segments, supported by acquisitions and capacity expansions. Despite a 12% YoY revenue growth in Q4 FY26, the company faces margin volatility and sector-specific risks, with its narrative centered on structural repositioning rather than broad-based growth.
Revenue grew 1.1% QoQ to ₹1,057 in Q3FY25.
⚠️ Margin pressure from Middle East disruptions and intense competition in agrochemicals, as flagged in filings.

Market Cap

₹11,656

P/E Ratio

56.1

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About JUBLINGREA 📊 Interactive Charts

📖 The Story

Jubilant Ingrevia Limited is in a strategic transition phase, shifting from commodity chemicals toward higher-margin Specialty Chemicals and Nutrition Health segments, supported by acquisitions and capacity expansions. Despite a 12% YoY revenue growth in Q4 FY26, the company faces margin volatility and sector-specific risks, with its narrative centered on structural repositioning rather than broad-based growth.

📰 What's Happening

In Q4 FY26, the company reported ₹1,179 crores in revenue (+12% YoY) and ₹278 crores in net profit (+11% YoY), with EBITDA margin expanding to 14% from 11% in FY25, driven by pricing pass-throughs and cost initiatives. Specialty Chemicals contributed 44% of revenue but 76% of EBITDA, highlighting margin accretion. Management completed an agro CDMO plant in 14 months with first shipments in March 2026 and acquired Remidex Pharma to accelerate human nutrition premixes. Capex of ₹69 crores was deployed for CDMO expansion, with sequential revenue growth expected from Q1FY27. The board recommended a final dividend of ₹2.50 per share (250% payout), payable within 30 days of the AGM, and reappointed J.K. Kabra & Co. as cost auditors for FY27.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	1,145	1,075	1,020	966	1,074	1,024	1,045	1,057
Operating Profit	111	125	126	104	101	119	135	148
OPM %	8.9%	10.8%	11.5%	9.9%	8.5%	10.7%	11.9%	13.1%
Net Profit	52	58	57	39	29	49	59	69
EPS	₹3.29	₹3.63	₹3.64	₹2.44	₹1.85	₹3.08	₹3.73	₹4.39

Revenue has shown consistent sequential growth from ₹1,024 crores in Q1FY25 to ₹1,179 crores in Q4FY26, with operating profit and net profit also trending upward. EBITDA margin improved from 10.7% in Q1FY25 to 14% in Q4FY26, reflecting operational efficiency and product mix shift. However, operating profit margin declined in earlier quarters like Q4FY24 (8.5%), indicating volatility. The company is investing in high-growth segments, as evidenced by capex deployment and acquisitions, while maintaining profitability in Nutrition & Health (14% margin) and Specialty Chemicals (27% margin).

🔮 Management Outlook & What's Next

Management expects sequential revenue growth to begin from Q1FY27, driven by expanded CDMO capacity and integration of Remidex Pharma. They highlighted the strategic shift toward higher-margin Specialty Chemicals and Nutrition Health segments, with no formal long-term guidance provided but confidence in sustained margin improvement from pricing power and cost initiatives. The acquisition of Remidex is positioned as a catalyst for accelerating growth in human nutrition premixes, aligning with long-term structural goals.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Chemicals & Petrochemicals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Solar Industries India Limited	1.57 L Cr	132.3	—	—	—
Pidilite Industries Limited	1.49 L Cr	75.7	—	—	—
SRF Limited	79,723	69.5	—	—	—
Linde India Limited	62,701	141.9	—	—	—
Gujarat Fluorochemicals Limited	40,793	89.6	—	—	—
Navin Fluorine International Limited	35,894	131.5	—	—	—
Himadri Speciality Chemical Limited	30,071	56.6	—	—	—
Deepak Nitrite Limited	24,911	33.3	—	—	—
Atul Limited	20,904	48.8	—	—	—
Tata Chemicals Limited	19,079	-47.1	—	—	—

🔗 Peer Stock Analyses

SOLARINDS PIDILITIND SRF LINDEINDIA FLUOROCHEM

⚠️ Risk Factors

1. Margin pressure from Middle East disruptions and intense competition in agrochemicals, as flagged in filings. 2. Oversupply conditions in China affecting pricing and utilization in the agrochemical segment. 3. Execution risks associated with integration of Remidex Pharma and expansion of CDMO capabilities. 4. Commodity price volatility impacting input costs and profitability in core chemical businesses.

📋 Recent Filings

🧠 Analyst's Read

Jubilant Ingrevia is executing a clear strategic pivot toward high-margin segments, supported by solid Q4 FY26 results and targeted investments. Investors should monitor execution of CDMO expansion, integration of Remidex, and margin sustainability amid external headwinds. The upcoming AGM and dividend approval will be key near-term catalysts.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on JUBLINGREA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when JUBLINGREA files new disclosures

Track JUBLINGREA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JUBLINGREA — Free

Free account · 2 AI queries/day